GKB Ophthalmics Ltd. demonstrates moderate revenue growth but faces significant profitability challenges with negative margins and returns. Among its peers, Poly Medicure Ltd. stands out as a strong performer in profitability and growth metrics, while several companies like Nureca Ltd. and GKB itself exhibit financial weaknesses. Investors should cautiously evaluate GKB, considering its growth potential against profitability risks.

• • Poly Medicure Ltd. shows the highest revenue growth and profitability metrics, making it the sector leader.
• • GKB has negative EPS and ROE, indicating financial stress despite decent revenue growth.
• • Nureca Ltd. and GKB Ophthalmics are among the financially weak companies with poor returns.